(19)
(11) EP 2 295 568 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A2)

(48) Corrigendum issued on:
26.10.2011 Bulletin 2011/43

(88) Date of publication A3:
20.04.2011 Bulletin 2011/16

(43) Date of publication:
16.03.2011 Bulletin 2011/11

(21) Application number: 10011987.4

(22) Date of filing: 16.10.2003
(27) Previously filed application:
 16.10.2003 PCT/IB03/05108
(51) International Patent Classification (IPC): 
C12N 15/10(2006.01)
A61K 38/10(2006.01)
 C12N 5/10(2006.01)
C07K 7/06(2006.01)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
AL LT LV MK

(30) Priority: 16.10.2002 EP 02292548

(62) Application number of the earlier application in accordance with Art. 76 EPC:
03769800.8 / 1551867

(71) Applicants:
  • Centre National de la Recherche Scientifique
    75016 Paris (FR)
  • Université de la Méditerranée
    13007 Marseille (FR)
  • Schafer-N
    2100 Copenhagen (DK)
  • Universitätsklinikum Hamburg-Eppendorf
    20246 Hamburg (DE)

(72) Inventors:
  • Rougon, Geneviève
    13009 Marseille (FR)
  • Torregrossa, Pascal
    1822 Chernex (CH)
  • Schachner, Melitta
    20251 Hamburg (DE)
  • Schafer, Nielsen, Claus
    3050 Humlebaek (DK)

(74) Representative: Leblois-Préhaud, Hélène Marthe Georgette et al
Cabinet Orès 36, rue de St Petersbourg
F-75008 Paris
F-75008 Paris (FR)

 
Remarks:
This application was filed on 30-09-2010 as a divisional application to the application mentioned under INID code 62.
 


(54) Use of poly-alpha2,8-sialic acid mimetic peptides to modulate NCAM functions


(57) The invention relates to the use of a peptide consisting of 5 to 30 amino acid residues, preferably 9 to 15, most preferably about 12 amino acid residues, said peptide comprising a B epitope of a poly-α2,8 sialic acid attached to NCAM, which is recognized by an anti-poly-α2,8 sialic acid (PSA) antibody, for the preparation of a medicament for modulating NCAM functions, to be administered for the prevention and/or the treatment of neurodegenerative diseases, brain and spine lesions, age-related learning and memory problems, and cancer.